We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Coronavirus Rampage Continues For Skechers, Guidance Withdrawn
Read MoreHide Full Article
Skechers U.S.A., Inc. (SKX - Free Report) , provided an update on the coronavirus outbreak, stating that it is temporarily closing its company-owned retail stores across North America as well as some parts of Europe. The shutdown is scheduled to last till Mar 28. Earlier, Skechers had announced closures of company-owned and third-party stores in various gravely-impacted international markets.
In yesterday’s release, the company withdrew its recently-provided guidance for first-quarter fiscal 2020 considering the current situation and its unpredictable impact on results. During fourth-quarter earnings call, management expected net sales in the band of $1.400-$1.425 billion for first-quarter 2020. Earnings per share were envisioned in the range of 70-75 cents. However, the company has withdrawn these forecasts.
We note that rising concerns related to the COVID-19 pandemic have disrupted economic activities globally. The crippling effect of the outbreak led to supply-chain disruptions, slowdown in production activities and reduced demand for several commodities. In the view of implementation of safety measures and drop in store footfall, companies are temporarily shutting their brick-and-mortar stores, curtailing work hours and operating in shifts or permitting employees to work remotely. The deadly virus has infected more than 190,000 people worldwide and death toll has crossed 7,500.
Recently, other footwear players that closed stores due to coronavirus outbreak are Crocs, Inc. (CROX - Free Report) , NIKE, Inc. (NKE - Free Report) , and Under Armour, Inc. (UAA - Free Report) among others.
Coming back to Skechers, the company has been grappling with concerns related to escalating operating expenses. Also, rising selling, general and administrative expenses due to higher advertising costs might hurt the company's margin and the bottom line. In the fourth quarter of 2019, SG&A expenses rose 25.5%. Additional spending in relation to its direct-to-consumer business and company-owned Skechers stores are also bumping up costs.
Nevertheless, the company is undertaking investments to improve infrastructure worldwide, primarily e-commerce platforms and distribution centers. We believe that strength in Skechers’ e-commerce business is likely to continue, given the technology investments.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Coronavirus Rampage Continues For Skechers, Guidance Withdrawn
Skechers U.S.A., Inc. (SKX - Free Report) , provided an update on the coronavirus outbreak, stating that it is temporarily closing its company-owned retail stores across North America as well as some parts of Europe. The shutdown is scheduled to last till Mar 28. Earlier, Skechers had announced closures of company-owned and third-party stores in various gravely-impacted international markets.
In yesterday’s release, the company withdrew its recently-provided guidance for first-quarter fiscal 2020 considering the current situation and its unpredictable impact on results. During fourth-quarter earnings call, management expected net sales in the band of $1.400-$1.425 billion for first-quarter 2020. Earnings per share were envisioned in the range of 70-75 cents. However, the company has withdrawn these forecasts.
We note that rising concerns related to the COVID-19 pandemic have disrupted economic activities globally. The crippling effect of the outbreak led to supply-chain disruptions, slowdown in production activities and reduced demand for several commodities. In the view of implementation of safety measures and drop in store footfall, companies are temporarily shutting their brick-and-mortar stores, curtailing work hours and operating in shifts or permitting employees to work remotely. The deadly virus has infected more than 190,000 people worldwide and death toll has crossed 7,500.
Recently, other footwear players that closed stores due to coronavirus outbreak are Crocs, Inc. (CROX - Free Report) , NIKE, Inc. (NKE - Free Report) , and Under Armour, Inc. (UAA - Free Report) among others.
Coming back to Skechers, the company has been grappling with concerns related to escalating operating expenses. Also, rising selling, general and administrative expenses due to higher advertising costs might hurt the company's margin and the bottom line. In the fourth quarter of 2019, SG&A expenses rose 25.5%. Additional spending in relation to its direct-to-consumer business and company-owned Skechers stores are also bumping up costs.
Nevertheless, the company is undertaking investments to improve infrastructure worldwide, primarily e-commerce platforms and distribution centers. We believe that strength in Skechers’ e-commerce business is likely to continue, given the technology investments.
We note that shares of this Zacks Rank #3 (Neutral) company have slumped 42% in the past six months compared with the industry’s decline of 20.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>